Published in Ann Intern Med on February 01, 1992
Transplants from the same donor. Ann Intern Med (1991) 1.43
Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study. Leukemia (2011) 4.47
Transactivation of a human cytomegalovirus early promoter by gene products from the immediate-early gene IE2 and augmentation by IE1: mutational analysis of the viral proteins. J Virol (1990) 4.01
International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders. Leukemia (2008) 3.41
Effect of lenalidomide therapy on mobilization of peripheral blood stem cells in previously untreated multiple myeloma patients. Leukemia (2007) 2.28
Cytogenetic findings in 200 patients with multiple myeloma. Cancer Genet Cytogenet (1995) 2.26
Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma. Blood (1997) 2.13
Brief report: alleviation of systemic manifestations of Castleman's disease by monoclonal anti-interleukin-6 antibody. N Engl J Med (1994) 2.13
Collapsing focal segmental glomerulosclerosis following treatment with high-dose pamidronate. J Am Soc Nephrol (2001) 2.10
High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin's lymphoma. N Engl J Med (1987) 1.98
Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP). Blood (1988) 1.95
Total therapy with tandem transplants for newly diagnosed multiple myeloma. Blood (1999) 1.89
Treatment outcomes in patients with relapsed and refractory multiple myeloma and high-risk cytogenetics receiving single-agent carfilzomib in the PX-171-003-A1 study. Leukemia (2013) 1.84
Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group. Leukemia (2012) 1.74
Management of treatment-emergent peripheral neuropathy in multiple myeloma. Leukemia (2011) 1.70
Oligoclonal protein bands and Ig isotype switching in multiple myeloma treated with high-dose therapy and hematopoietic cell transplantation. Blood (1998) 1.68
Graft-versus-myeloma effect: proof of principle. Blood (1996) 1.58
Jumping translocations of chromosome 1q in multiple myeloma: evidence for a mechanism involving decondensation of pericentromeric heterochromatin. Blood (1998) 1.58
Identification and expression of a human cytomegalovirus early glycoprotein. J Virol (1989) 1.50
Preceding standard therapy is the likely cause of MDS after autotransplants for multiple myeloma. Br J Haematol (1996) 1.46
Peripheral blood stem cell transplants for multiple myeloma: identification of favorable variables for rapid engraftment in 225 patients. Blood (1995) 1.45
Enrichment of human hematopoietic stem cell activity in the CD34+Thy-1+Lin- subpopulation from mobilized peripheral blood. Blood (1995) 1.26
IL-2-based immunotherapy after autologous transplantation for lymphoma and breast cancer induces immune activation and cytokine release: a phase I/II trial. Bone Marrow Transplant (2003) 1.22
Bone marrow transplants from HLA-identical siblings in advanced Hodgkin's disease. J Clin Oncol (1996) 1.22
High-dose chemoradiotherapy and autologous bone marrow transplantation for resistant multiple myeloma. Blood (1987) 1.15
Unique role of cytogenetics in the prognosis of patients with myeloma receiving high-dose therapy and autotransplants. J Clin Oncol (1997) 1.06
Tumor-specific recognition of human myeloma cells by idiotype-induced CD8(+) T cells. Blood (2000) 1.06
Comparable engraftment kinetics following peripheral-blood stem-cell infusion mobilized with granulocyte colony-stimulating factor with or without cyclophosphamide in multiple myeloma. J Clin Oncol (1998) 1.05
Successful treatment of systemic and central nervous system lymphomatoid granulomatosis with rituximab. Leuk Lymphoma (2004) 1.04
Salvage autologous or allogeneic transplantation for multiple myeloma refractory to or relapsing after a first-line autograft? Bone Marrow Transplant (1998) 1.03
Cure of multiple myeloma -- more hype, less reality. Bone Marrow Transplant (2006) 1.03
Hematopoietic cell transplantation for primary plasma cell leukemia: results from the Center for International Blood and Marrow Transplant Research. Leukemia (2011) 1.02
High-dose cyclophosphamide, carmustine, and etoposide and autologous bone marrow transplantation for relapsed Hodgkin's disease. Ann Intern Med (1986) 1.00
Tumor antigen immunization of sibling stem cell transplant donors in multiple myeloma. Bone Marrow Transplant (2005) 1.00
Inhibitory effects of extracellular products from oral bacteria on human fibroblasts and stimulated lymphocytes. Infect Immun (1978) 1.00
Amifostine and autologous hematopoietic stem cell support of escalating-dose melphalan: a phase I study. Biol Blood Marrow Transplant (2004) 0.98
Multiple myeloma: an old disease with new hope for the future. CA Cancer J Clin (2001) 0.97
Purified CD34+ Lin- Thy+ stem cells do not contain clonal myeloma cells. Blood (1995) 0.96
High dose chemotherapy followed by autologous hematopoietic rescue in Hodgkin's disease: long-term follow-up in 128 patients. Ann Oncol (1993) 0.96
Analysis of risk factors for the development of GVHD after T cell-depleted allogeneic BMT: effect of HLA disparity, ABO incompatibility, and method of T-cell depletion. Biol Blood Marrow Transplant (2001) 0.96
Incidence and impact of light chain associated (AL) amyloidosis on the prognosis of patients with multiple myeloma treated with autologous transplantation. Leuk Lymphoma (1997) 0.95
Autologous stem cell transplantation in multiple myeloma patients <60 vs >/=60 years of age. Bone Marrow Transplant (2003) 0.95
Tumor burden assessment and its implication for a prognostic model in advanced diffuse large-cell lymphoma. J Clin Oncol (1986) 0.94
Safety of autotransplants with high-dose melphalan in renal failure: a pharmacokinetic and toxicity study. Clin Cancer Res (1996) 0.94
Primary therapy with single agent bortezomib as induction, maintenance and re-induction in patients with high-risk myeloma: results of the ECOG E2A02 trial. Leukemia (2010) 0.94
Low-risk intensive therapy for multiple myeloma with combined autologous bone marrow and blood stem cell support. Blood (1992) 0.93
High-dose therapy for refractory multiple myeloma: improved prognosis with better supportive care and double transplants. Blood (1994) 0.92
UV light-induced reactivation of herpes simplex virus type 2 and prevention by acyclovir. J Infect Dis (1992) 0.92
Feasibility and cost-effectiveness of outpatient autotransplants in multiple myeloma. Bone Marrow Transplant (1997) 0.91
The role of vertebral augmentation in multiple myeloma: International Myeloma Working Group Consensus Statement. Leukemia (2008) 0.90
Autotransplants in multiple myeloma: what have we learned? Blood (1996) 0.90
Treatment of estrogen receptor-negative or hormonally refractory breast cancer with double high-dose chemotherapy intensification and bone marrow support. J Clin Oncol (1990) 0.90
Lymphomatoid granulomatosis following autologous stem cell transplantation. Bone Marrow Transplant (1999) 0.90
Preceding chemotherapy, tumour load and age influence engraftment in multiple myeloma patients mobilized with granulocyte colony-stimulating factor alone. Br J Haematol (2001) 0.89
Relapse of multiple myeloma after autologous transplantation: survival after salvage therapy. Bone Marrow Transplant (1995) 0.89
Biologic and therapeutic determinants of bone mineral density in multiple myeloma. Leuk Lymphoma (1998) 0.88
Allogeneic bone marrow transplantation for acute leukemia refractory to induction chemotherapy. Cancer (1985) 0.88
A comparison of marrow transplantation with chemotherapy for adults with acute leukemia of poor prognosis in first complete remission. J Clin Oncol (1988) 0.88
Collection, tumor contamination, and engraftment kinetics of highly purified hematopoietic progenitor cells to support high dose therapy in multiple myeloma. Blood (1998) 0.88
Rejection of stable cultured allografts by active or passive (adoptive) immunization. Proc Natl Acad Sci U S A (1982) 0.86
A multicenter phase 2 trial of stem cell transplantation for immunoglobulin light-chain amyloidosis (E4A97): an Eastern Cooperative Oncology Group Study. Bone Marrow Transplant (2004) 0.86
A novel multiparametric approach for analysis of cytoplasmic immunoglobulin light chains by flow cytometry. Mod Pathol (2001) 0.86
Plasma cell dyscrasias. JAMA (1992) 0.86
Stimulators and inhibitors of lymphocyte DNA synthesis in supernatants from human lymphoid cell lines. J Immunol (1979) 0.85
Stage IV diffuse large-cell lymphoma: a long-term analysis. J Clin Oncol (1985) 0.84
Therapeutic dilemmas with thalidomide in multiple myeloma: case discussions. Semin Oncol (2001) 0.84
Recombinant human granulocyte colony-stimulating factor hastens granulocyte recovery after high-dose chemotherapy and autologous bone marrow transplantation in Hodgkin's disease. J Clin Oncol (1989) 0.84
High-dose methylprednisolone treatment for acute graft-versus-host disease after bone marrow transplantation in adults. Transplantation (1984) 0.84
Melphalan plus total body irradiation (MEL-TBI) or cyclophosphamide (MEL-CY) as a conditioning regimen with second autotransplant in responding patients with myeloma is inferior compared to historical controls receiving tandem transplants with melphalan alone. Bone Marrow Transplant (2000) 0.83
Activation of human lymphocytes by supernatants from human thymic epithelium. Clin Exp Immunol (1979) 0.83
Appearanc of cytotoxic cells within the bronchus after local infection with herpes simplex virus. J Immunol (1977) 0.82
Activity of single-agent melphalan 220-300 mg/m2 with amifostine cytoprotection and autologous hematopoietic stem cell support in non-Hodgkin and Hodgkin lymphoma. Bone Marrow Transplant (2004) 0.82
Obstructive lung disease after allogeneic bone marrow transplantation. Transplantation (1984) 0.81
Engraftment syndrome after autologous hematopoietic stem cell transplant supported by granulocyte-colony-stimulating factor (G-CSF) versus granulocyte-macrophage colony-stimulating factor (GM-CSF). Bone Marrow Transplant (2003) 0.81
Active and suppressor T cells: diminution in a patient with dyskeratosis congenita and in first-degree relatives. Gerontology (1979) 0.80
High-dose therapy with autologous haemopoietic stem cell support for Waldenström's macroglobulinaemia. Br J Haematol (1999) 0.80
Results of recent salvage chemotherapy regimens for lymphoma and Hodgkin's disease. Semin Hematol (1988) 0.79
Risk classification as the basis for clinical staging of diffuse large-cell lymphoma derived from 10-year survival data. Blood (1989) 0.79
Relapsed multiple myeloma. Curr Treat Options Oncol (2001) 0.79
High-dose chemotherapy with carboplatin, cyclophosphamide and etoposide and autologous transplantation for multiple myeloma relapsing after a previous transplant. Bone Marrow Transplant (1997) 0.79
Stages I and II diffuse large cell lymphomas: prognostic factors and long-term results with CHOP-bleo and radiotherapy. Blood (1991) 0.79
Treatment of AL-amyloidosis with dexamethasone plus alpha interferon. Leuk Lymphoma (1997) 0.78
Immunomagnetic removal of CALLA positive cells from human bone marrow. Lancet (1983) 0.78